Zoetis Q1 2026 Earnings Call Insights
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy ZTS?
Source: seekingalpha
- Flat Revenue Performance: Zoetis reported global revenue of $2.3 billion for Q1 2026, with a 3% reported growth but flat organic operational revenue, indicating signs of weakened market demand, particularly in the companion animal segment.
- International Growth: The international segment achieved 10% organic operational revenue growth, while the U.S. market declined by 8%, suggesting an uneven performance across global markets that may impact future strategic positioning.
- Acquisition to Expand Capabilities: Zoetis announced the acquisition of Neogen's animal genomics business, aimed at enhancing its capabilities in livestock genetics, which could provide new growth avenues amid a competitive market landscape.
- Revised Earnings Outlook: The company has lowered its 2026 revenue guidance to a range of $9.68 billion to $9.96 billion, expecting organic operational revenue growth of 2% to 5%, reflecting the response to uncertainties and competitive pressures in the market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ZTS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ZTS
Wall Street analysts forecast ZTS stock price to rise
12 Analyst Rating
7 Buy
5 Hold
0 Sell
Moderate Buy
Current: 87.310
Low
130.00
Averages
154.20
High
200.00
Current: 87.310
Low
130.00
Averages
154.20
High
200.00
About ZTS
Zoetis Inc. is a global animal health company. The Company is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. The Company operates through two segments: the United States (U.S.) and International. Within each of these operating segments, it offers a diversified product portfolio, including vaccines, anti-infectives, parasiticides, dermatology, pain and sedation, other pharmaceutical, and animal health diagnostics, for both companion animal and livestock customers. It directly markets its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. The Company is engaged in commercializing products across eight species: dogs, cats and horses (collectively, companion animals) and cattle, poultry, swine, fish and sheep (collectively, livestock).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Zoetis Shares Drop 20% After Subpar Q1 Earnings Report
- Subpar Performance: Zoetis reported a 3% increase in Q1 sales, meeting analyst expectations, but adjusted earnings per share rose only 9%, significantly below Wall Street forecasts, resulting in a 20% drop in share price.
- Weak Future Guidance: The company's guidance for organic operational revenue and adjusted earnings-per-share growth of 3.5% and 4% for mid-2026 fell short of market consensus, indicating pressure on future growth prospects.
- Changing Market Demand: CEO Kristen Peck highlighted that pet owners are showing decreased demand for premium products, reflecting increased sensitivity to macroeconomic pressures on pet care spending in the U.S., particularly amid rising economic uncertainty.
- Increased Competition and Innovation Needs: While U.S. pet segment revenue declined by 11%, livestock and international sales grew by 12% and 10%, respectively, Zoetis must rely on innovation to drive future growth, with expected approvals for new treatments potentially aiding short-term performance.
See More
Memory Chip Stocks Surge but Face Potential Decline
- Memory ETF Surge: The Roundhill Memory ETF (DRAM) surged nearly 30% this week, reflecting strong performance in memory chip and data storage stocks driven by AI trades, despite modest overall market gains.
- Outstanding Individual Stocks: Qualcomm rose over 23% this week, while Micron soared nearly 37%, marking its best weekly performance since 2008; however, both stocks have relative strength indices (RSI) exceeding 80, indicating potential pullback risks.
- Overbought and Oversold Dynamics: Qualcomm's RSI stands at 86, with a consensus hold rating among analysts, predicting a 22% drop to reach the price target, while Micron's RSI is at 82, rated buy by most analysts, yet still has a 23% downside potential.
- EPAM and Zoetis Under Pressure: EPAM Systems has an RSI of 18 after falling over 11% due to a revenue growth outlook cut, while Zoetis dropped more than 27% after missing first-quarter earnings expectations, with an RSI close to 15, indicating strong oversold signals.
See More
Healthcare Stocks Decline Late Friday Afternoon
- Healthcare Sector Decline: Late Friday afternoon, the NYSE Healthcare Index experienced a decline, indicating a weakening market confidence in the healthcare sector, which may affect investors' short-term decisions.
- Market Sentiment Deterioration: The widespread drop in healthcare stocks could lead investors to reassess their portfolios in the healthcare sector, resulting in increased capital outflows and heightened market volatility.
- Significant Industry Impact: The decline in healthcare stocks may trigger a ripple effect on related companies' stock prices, impacting their financing capabilities and future growth expectations, especially in the current uncertain economic environment.
- Investor Focus Shift: As healthcare stocks weaken, investors may redirect their attention to other sectors in search of more attractive investment opportunities, potentially affecting capital inflows into the healthcare industry.
See More
US Stocks Close Lower Amid Cautious Market Sentiment
- Market Weakness: On Thursday, the S&P 500 Index fell by 0.38%, the Dow Jones Industrial Average dropped by 0.63%, and the Nasdaq 100 Index decreased by 0.12%, reflecting investor skepticism regarding a potential US-Iran peace deal, which led to a reversal of early gains and impacted market confidence.
- Economic Data Support: Despite the market decline, initial jobless claims rose by 10,000 to 200,000, below the expected 205,000, indicating resilience in the labor market, while Q1 nonfarm productivity increased by 0.8%, surpassing the 0.6% forecast, providing some support to the market.
- Earnings Report Impact: As of Thursday, 84% of the 425 S&P 500 companies that reported earnings exceeded expectations, with Q1 earnings projected to rise by 12% year-over-year, although growth outside the tech sector is only expected to be around 3%, indicating a divergence that may influence investor allocation strategies.
- Oil Price Recovery: WTI crude oil prices rebounded after a 4% decline on Thursday, as the market focused on the potential resumption of US military operations to ensure safe passage through the Strait of Hormuz, which is expected to have ongoing implications for global oil prices and related stocks.
See More
Zoetis Q1 2026 Earnings Call Insights
- Flat Revenue Performance: Zoetis reported global revenue of $2.3 billion for Q1 2026, with a 3% reported growth but flat organic operational revenue, indicating signs of weakened market demand, particularly in the companion animal segment.
- International Growth: The international segment achieved 10% organic operational revenue growth, while the U.S. market declined by 8%, suggesting an uneven performance across global markets that may impact future strategic positioning.
- Acquisition to Expand Capabilities: Zoetis announced the acquisition of Neogen's animal genomics business, aimed at enhancing its capabilities in livestock genetics, which could provide new growth avenues amid a competitive market landscape.
- Revised Earnings Outlook: The company has lowered its 2026 revenue guidance to a range of $9.68 billion to $9.96 billion, expecting organic operational revenue growth of 2% to 5%, reflecting the response to uncertainties and competitive pressures in the market.
See More
U.S. Stock Market Retreats as Oil Prices Surge
- Market Retreat: The S&P 500 Index fell by 0.40%, the Dow Jones Industrial Average by 0.51%, and the Nasdaq 100 by 0.28%, indicating a retreat in market sentiment as rising oil prices weigh on investor confidence and raise concerns about future economic prospects.
- Strong Employment Data: Initial jobless claims in the U.S. rose by 10,000 to 200,000, indicating a stronger labor market than the expected 205,000, while continuing claims unexpectedly fell by 10,000 to a 2.25-year low of 1.766 million, showcasing economic resilience.
- Productivity and Costs: U.S. Q1 nonfarm productivity increased by 0.8%, surpassing expectations of 0.6%, while unit labor costs rose by 2.3%, below the anticipated 2.5%, which may influence future inflation expectations and Fed policy decisions.
- Fed Policy Outlook: Boston Fed President indicated that interest rates should remain at “mildly restrictive” levels, suggesting that if inflation trends worsen significantly, a reassessment of policy would be necessary, with markets pricing in only a 6% chance of a rate cut at the next FOMC meeting.
See More
Zoetis Shares Drop 20% After Subpar Q1 Earnings Report
- Subpar Performance: Zoetis reported a 3% increase in Q1 sales, meeting analyst expectations, but adjusted earnings per share rose only 9%, significantly below Wall Street forecasts, resulting in a 20% drop in share price.
- Weak Future Guidance: The company's guidance for organic operational revenue and adjusted earnings-per-share growth of 3.5% and 4% for mid-2026 fell short of market consensus, indicating pressure on future growth prospects.
- Changing Market Demand: CEO Kristen Peck highlighted that pet owners are showing decreased demand for premium products, reflecting increased sensitivity to macroeconomic pressures on pet care spending in the U.S., particularly amid rising economic uncertainty.
- Increased Competition and Innovation Needs: While U.S. pet segment revenue declined by 11%, livestock and international sales grew by 12% and 10%, respectively, Zoetis must rely on innovation to drive future growth, with expected approvals for new treatments potentially aiding short-term performance.
See More
Memory Chip Stocks Surge but Face Potential Decline
- Memory ETF Surge: The Roundhill Memory ETF (DRAM) surged nearly 30% this week, reflecting strong performance in memory chip and data storage stocks driven by AI trades, despite modest overall market gains.
- Outstanding Individual Stocks: Qualcomm rose over 23% this week, while Micron soared nearly 37%, marking its best weekly performance since 2008; however, both stocks have relative strength indices (RSI) exceeding 80, indicating potential pullback risks.
- Overbought and Oversold Dynamics: Qualcomm's RSI stands at 86, with a consensus hold rating among analysts, predicting a 22% drop to reach the price target, while Micron's RSI is at 82, rated buy by most analysts, yet still has a 23% downside potential.
- EPAM and Zoetis Under Pressure: EPAM Systems has an RSI of 18 after falling over 11% due to a revenue growth outlook cut, while Zoetis dropped more than 27% after missing first-quarter earnings expectations, with an RSI close to 15, indicating strong oversold signals.
See More
Healthcare Stocks Decline Late Friday Afternoon
- Healthcare Sector Decline: Late Friday afternoon, the NYSE Healthcare Index experienced a decline, indicating a weakening market confidence in the healthcare sector, which may affect investors' short-term decisions.
- Market Sentiment Deterioration: The widespread drop in healthcare stocks could lead investors to reassess their portfolios in the healthcare sector, resulting in increased capital outflows and heightened market volatility.
- Significant Industry Impact: The decline in healthcare stocks may trigger a ripple effect on related companies' stock prices, impacting their financing capabilities and future growth expectations, especially in the current uncertain economic environment.
- Investor Focus Shift: As healthcare stocks weaken, investors may redirect their attention to other sectors in search of more attractive investment opportunities, potentially affecting capital inflows into the healthcare industry.
See More
US Stocks Close Lower Amid Cautious Market Sentiment
- Market Weakness: On Thursday, the S&P 500 Index fell by 0.38%, the Dow Jones Industrial Average dropped by 0.63%, and the Nasdaq 100 Index decreased by 0.12%, reflecting investor skepticism regarding a potential US-Iran peace deal, which led to a reversal of early gains and impacted market confidence.
- Economic Data Support: Despite the market decline, initial jobless claims rose by 10,000 to 200,000, below the expected 205,000, indicating resilience in the labor market, while Q1 nonfarm productivity increased by 0.8%, surpassing the 0.6% forecast, providing some support to the market.
- Earnings Report Impact: As of Thursday, 84% of the 425 S&P 500 companies that reported earnings exceeded expectations, with Q1 earnings projected to rise by 12% year-over-year, although growth outside the tech sector is only expected to be around 3%, indicating a divergence that may influence investor allocation strategies.
- Oil Price Recovery: WTI crude oil prices rebounded after a 4% decline on Thursday, as the market focused on the potential resumption of US military operations to ensure safe passage through the Strait of Hormuz, which is expected to have ongoing implications for global oil prices and related stocks.
See More
Zoetis Q1 2026 Earnings Call Insights
- Flat Revenue Performance: Zoetis reported global revenue of $2.3 billion for Q1 2026, with a 3% reported growth but flat organic operational revenue, indicating signs of weakened market demand, particularly in the companion animal segment.
- International Growth: The international segment achieved 10% organic operational revenue growth, while the U.S. market declined by 8%, suggesting an uneven performance across global markets that may impact future strategic positioning.
- Acquisition to Expand Capabilities: Zoetis announced the acquisition of Neogen's animal genomics business, aimed at enhancing its capabilities in livestock genetics, which could provide new growth avenues amid a competitive market landscape.
- Revised Earnings Outlook: The company has lowered its 2026 revenue guidance to a range of $9.68 billion to $9.96 billion, expecting organic operational revenue growth of 2% to 5%, reflecting the response to uncertainties and competitive pressures in the market.
See More
U.S. Stock Market Retreats as Oil Prices Surge
- Market Retreat: The S&P 500 Index fell by 0.40%, the Dow Jones Industrial Average by 0.51%, and the Nasdaq 100 by 0.28%, indicating a retreat in market sentiment as rising oil prices weigh on investor confidence and raise concerns about future economic prospects.
- Strong Employment Data: Initial jobless claims in the U.S. rose by 10,000 to 200,000, indicating a stronger labor market than the expected 205,000, while continuing claims unexpectedly fell by 10,000 to a 2.25-year low of 1.766 million, showcasing economic resilience.
- Productivity and Costs: U.S. Q1 nonfarm productivity increased by 0.8%, surpassing expectations of 0.6%, while unit labor costs rose by 2.3%, below the anticipated 2.5%, which may influence future inflation expectations and Fed policy decisions.
- Fed Policy Outlook: Boston Fed President indicated that interest rates should remain at “mildly restrictive” levels, suggesting that if inflation trends worsen significantly, a reassessment of policy would be necessary, with markets pricing in only a 6% chance of a rate cut at the next FOMC meeting.
See More
